ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include: Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis. U.S. Glaucoma record net sales of $118.6 mil
